Abstract:BACKGROUNDPrevious reports have documented protein phosphatase 1 (PP1) as an essential androgen receptor (AR) activator. However, more systemic studies are needed to further define PP1 effects on AR, particularly in the settings of prostate cancer cells and under conditions mimicking androgen ablation. METHODSPP1 effects on AR protein expression, degradation, ubiquitination, and stabilization were examined in non-prostate cancer cells, followed by validation on exogenous settings in androgen-sensitive (LNCaP and VCaP) and castration-resistant (C4-2) prostate cancer cells. Effects of PP1 on AR protein expression, on AR-mediated transcription of exogenous reporter and endogenous gene, and on LNCaP and C4-2 cell proliferation were monitored under androgen-containing versus androgen-depleted conditions to assess the effects of PP1 on AR responsiveness to androgen. RESULTSIn this report, we determined that PP1 functions to stabilize AR proteins that exclusively undergo the proteasome-dependent degradation, and the stimulatory effects of PP1 were predominantly mediated by the AR ligand-binding domain (LBD). Consistently, PP1 enhances AR protein stability by disrupting the LBD-mediated and K48-linked ubiquitination cascade. We further validated the above findings in the prostate cancer cells by showing that PP1 inhibition can increase ubiquitin- and proteasome-dependent degradation of endogenous AR under androgen deprivation. Significantly, we found that PP1 could markedly activate AR transcriptional activities under conditions mimicking androgen ablation and that androgen sensitivity was substantially evoked by PP1 inhibition in the prostate cancer cell lines. CONCLUSIONSAs summarized in a simplified model, our studies defined an essential PP1-mediated pathway for AR protein stabilization that can compensate the loss of androgen and established a mechanistic link between PP1 and androgen responsiveness. The amplified PP1-dependence for AR activation under the androgen ablated conditions provides a rationale to therapeutically target the PP1-AR module in the castration-resistant prostate cancer (CRPC). Our findings also suggested an alternative AR-targeting compounds screening strategy that aims to circumvent PP1-AR interaction. Prostate 76:649-661, 2016. (c) 2016 Wiley Periodicals, Inc.

Phosphorylation of the androgen receptor at Ser81 is co‐sustained by CDK1 and CDK9 and leads to AR‐mediated transactivation in prostate cancer

Androgen receptor cofactors: A potential role in understanding prostate cancer

Androgen Ablation Elicits PP1-dependence for AR Stabilization and Transactivation in Prostate Cancer

Regulation of Androgen Receptor Activity by Tyrosine Phosphorylation

Protein Phosphatase 1 Suppresses Androgen Receptor Ubiquitylation and Degradation

The Androgen Receptor and Its Crosstalk with the Src Kinase During Castrate-Resistant Prostate Cancer Progression

AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer

PC-1 Works in Conjunction with E3 Ligase CHIP to Regulate Androgen Receptor Stability and Activity

AR-dependent phosphorylation and phospho-proteome targets in prostate cancer

Phosphorylation/Dephosphorylation of Androgen Receptor as a Determinant of Androgen Agonistic or Antagonistic Activity

Suppression of Androgen Receptor Transactivation by Pyk2 Via Interaction and Phosphorylation of the ARA55 Coregulator*

Plk1-dependent microtubule dynamics promotes androgen receptor signaling in prostate cancer.

Increased Prlz-Mediated Androgen Receptor Transactivation Promotes Prostate Cancer Growth At Castration-Resistant Stage

Activation of P-TEFb by Androgen Receptor-Regulated Enhancer RNAs in Castration-Resistant Prostate Cancer.

Androgen receptor monomers and dimers regulate opposing biological processes in prostate cancer cells

CRISPR screening identifies CDK12 as a conservative vulnerability of prostate cancer

Modulating Androgen Receptor-Driven Transcription in Prostate Cancer with Selective CDK9 Inhibitors.

Androgen Receptor Signaling and Spatial Chromatin Organization in Castration-Resistant Prostate Cancer

The MYH9 Cytoskeletal Protein is a Novel Corepressor of Androgen Receptors

Differential Regulation of Androgen Receptor by Pim-1 Kinases Via Phosphorylation-Dependent Recruitment of Distinct Ubiquitin E3 Ligases